Document:

Exhibit 10.21

 

SECOND AMENDED AND RESTATED ADVISER’S
AGREEMENT

 

This Amended Advisers Agreement
(the "Agreement") is entered into as of June 15, 2011 (the “Effective Date”) by and between Hemispherx BioPharma,
Inc., a Delaware corporation ("Company"), and The Sage Group, Inc. and its employees, Principals, and Senior Directors
(“Adviser”), a New Jersey corporation, and amends and restates in its entirety the Adviser’s Agreement between
the parties dated October 2, 2008, as amended on July 15, 2010, and the Master Agreement dated March 31, 2009, with respect to
the following:

 

A.           Adviser
represents that it has knowledge of and contacts with companies which have the potential to become partners of various types with
Company and that Adviser represents that it has experience and expertise that can be used to facilitate and help close such transactions
for the benefit of the Company.

 

B.           Company
is agreeable to having Adviser act in such capacities and Company and Adviser hereby agree that Company appoints Adviser and Adviser
agrees to use all reasonable efforts to help increase the value of the Company.

 

C.           Definitions:

 

“Transaction”
means a licensing, partnering, distribution, alliance, or similar transaction pertaining to and promoting the sale of the Company’s
products and technologies, including but not limited to, any and all uses for Ampligen, Alferon, and related intellectual property.
A Transaction also means the acquisition of companies in whole or in part and the sale or the merger of Company. For clarity, non-revenue
producing agreements such as an MTA, a clinical research agreement or feasibility study is not a Transaction hereunder. Should
a Transaction not be introduced to Company by Adviser and/or should Company decide for whatever reason, to not involve Adviser
in a possible Transaction, then such transaction will not be a Transaction. However, it is the intention of the parties that the
Adviser be an active participant in all material transactions of the Company. A Transaction is any Transaction that occurs during
the Term or 18 months thereafter.

 

“Consideration”
means any monies, fungible and market-based securities and/or other valuable cash consideration that Company and/or its Subsidiaries
receives as a result of a Transaction.

 

D.           Independent
Contractor. Adviser is and at all times shall be an independent contractor in all matters relating to this Agreement. Adviser
and its employees are not agents of Company for any purposes and have no power or authority, whether apparent, actual, ostensible
or otherwise, to bind or commit Company in any way. Transactions shall first be approved in writing by the Company, so as to avoid
any dispute as to Adviser’s entitlement to payment of its fees, and Adviser efforts toward such approved Transactions will
be as directed and agreed by the Company.

 

    	1

    	 

    

 

E.           Adviser's
Fee. In consideration for the Services to be performed by Adviser hereunder, Company shall pay to Adviser a fee ("Adviser's
Fee") of:

 

1.         Monthly
Fee: A monthly fee of $20,000 payable, at Company’s option in cash or shares for the Term of this Agreement.

 

2.         Options:
On the date this Agreement is fully executed by all parties (the “Execution Date”), the Company will issue one-time
common stock Options with an exercise price equal to 110% of the closing price of the Company stock on the NYSE/ Amex on the effective
trading date immediately preceding the date this agreement executed by all parties, to the following Sage personnel under the Company’s
Equity Incentive Plan of 2009. 

 

	Wayne Pambianchi	 	 	175,000	 
	 	 	 	 	 
	Doug Hulse	 	 	5,000	 
	 	 	 	 	 
	Chuck Casamento	 	 	5,000	 
	 	 	 	 	 
	Gordon Ramseier	 	 	5,000	 
	 	 	 	 	 
	Bill Mason	 	 	5,000	 
	 	 	 	 	 
	Dan Tripodi	 	 	5,000	 

 

		a.	All options issued pursuant to this subsection shall vest on the first anniversary of the date
of award. All options issued pursuant to this subsection not vested at the time of termination of this Agreement with the Company
shall immediately become void.

 

3.           Success
Fees

 

		a.	Five (5%) of all Consideration with such Success Fees capped at $5 million per annum.

 

4.           At
the sole and absolute discretion and formal approval of and by the Board of Directors of the Company, Adviser may receive bonuses
for extraordinary performance or special projects which may include, without limitation, efforts to gain security analyst coverage,
connections to financing sources, assessment of unique business opportunities and the like, as determined by Company, providing
such bonuses do not exceed $250,000 per year. 

 

F.           Expenses.
Company shall reimburse Adviser for reasonable out-of pocket expenses that are pre-approved by Company.

 

G.           No
Obligation. Adviser acknowledges that the decision to enter into any Transaction rests solely with the Company and the Company
is NOT obliged to enter any Transaction proffered by Adviser.

 

    	2

    	 

    

 

H.           Prohibitions;
Compliance with Laws. Adviser shall not make any representations or warranties on behalf of Company to any third party, it
being understood that such representations and warranties will be made only by the Company. Adviser shall execute and function
in full compliance with the Company’s “Code Of Ethics And Business Conduct For Officers, Directors, Employees, Agents
And Consultants”.

 

I.           Amended
Term and Termination. This Agreement is effective as of the date hereof and shall continue for 24 months from the Effective
Date and terminates upon the expiration of the 24 month period. Further, this Agreement may be terminated by Company for cause
after the Company delivers written notice to Adviser of a failure to perform and such failure is not cured within fifteen (15)
days.

 

J.           Reliance.
Company acknowledges that all opinions and advice (oral or written) given by Adviser to Company in connection with Adviser’s
engagement hereunder, are intended solely for the benefit and use of Company in considering the matters to which they relate, and
Company agrees that no such opinion or advice shall be used for any other purpose or reproduced, disseminated, quoted or referred
to at any time, in any manner or be made by the Company (or such persons), without Adviser’s express written consent, which
consent shall not be unreasonably withheld.

 

K.           Liability.
In furnishing Company with contact, advice and other services, neither Adviser nor any officer, director or agent thereof shall
be liable to Company or its creditors for errors of judgment or for any other act except willful malfeasance, bad faith or gross
negligence in the performance of Adviser’s duties, or reckless disregard of its obligations and duties under the terms of
this Agreement. Company will indemnify Adviser against all claims and damages including legal fees.

 

L.           General
Provisions.

 

1.         Governing
Law; Severability. This Agreement shall be governed by and under the laws of the State of Pennsylvania without giving effect
to conflicts of law principles. If any provision hereof is found invalid or unenforceable, that part shall be amended to achieve
as nearly as possible the same effect as the original provision and the remainder of this Agreement shall remain in full force
and effect.

 

2.         Disputes.
Any dispute arising under or in any way related to this Agreement shall be submitted to binding arbitration by the American Arbitration
Association in accordance with that Association's commercial rules then in effect.

 

3.         Confidential
Information. Adviser acknowledges that, in the course of performing its duties under this Agreement, it may obtain information
relating to Company that is not available to the public ("Confidential Information"). Adviser shall execute with this
Agreement the customary form of Confidentiality or Non-Disclosure Agreement used by Company.

 

    	3

    	 

    
 

4.         Entire
Agreement. This Agreement constitutes the entire agreement and final understanding of the parties with respect to the subject
matter hereof and supersedes and terminates all prior and/or contemporaneous understandings, agreements and/or discussions between
the parties, whether written or verbal, express or implied, relating in any way to the subject matter hereof including, but not
limited any other arrangements between the parties for contingency fees. This Agreement may not be altered, amended, modified or
otherwise changed in any way except by a written agreement, signed by both parties and with prior approval of the Board of Directors
of the Company.

 

5.         Notices.
Any notice or other communication pursuant hereto shall be given to a party at its address below its signature hereto by (i) personal
delivery, (ii) commercial overnight delivery service with written verification of receipt, or (iii) registered or certified mail.
If so mailed or delivered, a notice shall be deemed given on the earlier of the date of actual receipt or three days after the
date of transmission by authorized means.

 

6.         Nonassignability.
Neither this Agreement, nor any rights, duties or interest herein, shall be assigned, transferred, pledged, hypothecated or otherwise
conveyed by either party without the prior written consent of the other party. Any such attempted conveyance in violation of this
paragraph shall be void and shall constitute a default entitling the other party to terminate this Agreement.

 

IN WITNESS WHEREOF, the
Company and Adviser have executed this Agreement effective as of the date set forth above.

 

	HEMISPHERX BIOPHARMA, INC.	 	THE SAGE GROUP, INC.
	1617 JFK Boulevard	 	1802 Route 31 North, Suite 381
	6th Floor	 	Clinton, NJ  08809
	Philadelphia, PA  19103	 	 
	 	 	 	 
	By:	/s/ William A. Carter	 	By:	/s/ Wayne Pambianchi
	 	Dr. William Carter, MD	 	 	Wayne Pambianchi
	 	Chairman and CEO	 	 	Executive Director

 

	Date: 	12/14/11	 	Date: 	12/13/11	 

 

    	4Exhibit 10.22

 

Fourth
Amendment to Supply Agreement

 

This Amendment (this
“Amendment”) effective as of March 11, 2011 (the “Amendment Date”) to the Supply
Agreement (the “Agreement”), entered into on December 8,
2005, and previously amended on February 28, 2006, September 5, 2006, and February 26, 2010, between Hemispherx Biopharma, Inc.
(hereinafter “Hemispherx”), and Jubilant HollisterStier LLC (formerly known as Hollister-Stier Laboratories
LLC (hereinafter “Hollister-Stier”). Hemispherx and Hollister-Stier are each a “Party” and
collectively, the “Parties”.

 

Whereas,
the Parties wish to amend the Agreement regarding, among other things, postponement and cancellation of purchase orders; and

 

Whereas,
all terms used, but not defined, herein shall have the respective meanings set forth in the Agreement.

 

Now,
Therefore, in consideration of the premises and of the covenants herein contained, the Parties mutually agree as follows:

 

		1.	Amendments.

 

(a) Section 3.8.2.2 of the Agreement is amended
and restated in its entirety as follows:

 

3.8.2.2 Hemispherx reserves the right
to cancel or postpone any purchase order, provided that all postponements and cancellations are in accordance with each of the
following terms:

 

		3.8.2.2.1	Should Hemispherx cancel or postpone all or part of any purchase order  * or fewer calendar days prior to the
scheduled fill date, Hemispherx shall pay Hollister-Stier a  *  fee equivalent to   *   of
the purchase price for the entire purchase order.

 

		3.8.2.2.2	Should Hemispherx cancel or postpone all or part of any purchase order less than    *  calendar
days, but more than    *  calendar days prior to the scheduled fill date, Hemispherx shall
pay Hollister-Stier  a  *   fee equal to   *   of the purchase
price for the entire purchase order.

 

		3.8.2.2.3	Should Hemispherx cancel or postpone all or part of any purchase order less than    *  calendar
days, but more than    *  calendar days prior to the scheduled fill date, Hemispherx shall pay Hollister-Stier a  *  fee equal to   *   of the purchase price for the entire purchase order.

 

		3.8.2.2.4	Should Hemispherx cancel or postpone a purchase order    *  or more days before the scheduled
fill date, Hollister-Stier will    *    . 

 

* Portions of this exhibit have been omitted
pursuant to a request for confidential treatment and have been filed separately with the Commission.

 Confidential

 

    	1

    	 

    

 

		3.8.2.2.5	The fees imposed under this Section 3.8.2.2 are    *    that will be imposed upon a
rescheduled purchase order.

 

(b) The following is appended to Section 3.8.3.:
“The prices as of March 11, 2011, which are subject to increase on the next anniversary of the Effective Date are set forth
on Exhibit B.”

 

(c) The Exhibit to this Amendment is appended
to the Agreement, as Exhibit B.

 

(d)
Section 8.1 is amended by replacing such Section with: “This Agreement shall remain in full force and effect for   3  years
from the effective date of this Amendment, unless terminated earlier in accordance with the provisions hereof.

 

		2.	Miscellaneous.

 

2.1          Continuing
Effect. This Amendment shall be effective for all purposes as of the Amendment Date. Except as otherwise expressly modified
by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.

 

2.2          Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.

 

2.3          Governing
Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Washington, irrespective
of any conflicts of law rule which may direct or refer such determination of applicable law to any other state, and if this Amendment
were performed wholly within the State of Washington.

 

* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.

 Confidential

 

    	2

    	 

    

 

In
Witness Whereof, the Parties have executed this Amendment effective as of the Amendment Date.

 

	Hemispherx Biopharma, Inc.
	 
	By:	/s/ William A. Carter	 
	 	 	 
	Name:	 William A. Carter, M.D.	 
	 	 	 
	Title:	 CEO	 
	 	 	 
	Date:	 9/9/11	 
	 	 	 
	Jubilant HollisterStier LLC
	 	 	 
	By:	/s/ Marcelo Morales	 
	 	 	 
	Name:	 Marcelo Morales	 
	 	 	 
	Title:	 CEO	 
	 	 	 
	Date:	 Sept 2, 2011	 

 

* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.

Confidential

 

    	3

    	 

    

 

EXHIBIT TO AMENDMENT FORMING EXHIBIT
B TO SUPPLY AGREEMENT

PRICING AS OF MARCH 11, 2011

 

 

 

	December 8, 2010	

 

Mr. Wayne Springate

Hemispherx Biopharma, Inc.

783 Jersey Ave.

New Brunswick, NJ 08901

 

RE: Document 576-2-25-0, 2011 Price Increase - Ampligen

 

Dear Mr. Springate:

 

Per Supply Agreement dated December 8, 2005, Section 3.8.3, Hollister-Stier
is notifying you of a    *   increase in pricing for fill/finish services provided to Hemispherx
Biopharma. Changes in pricing are based upon the annual percentage change in the Producer Price Index Industry:

Pharmaceutical Preparations. Pricing for product lots manufactured
December 8, 2010 through December 7, 2011 will be as follows:

 

	AMPLIGEN
	CURRENT PRICING	 	PROPOSED PRICING
	Media Fill Batch:	$          *	 	Media Fill Batch:	$          *
	Development Batch:	$          *	 	Development Batch:	$          *
	Registration/Commercial Batches:	$          *	 	Registration/Commercial Batches:	$          *

 

As always, we appreciate your business and
remain dedicated to the high standards of quality you

rely upon. If you have any questions, please feel free to contact me directly at 509-482-3541.

 

Best regards,

/s/David M. Flowers

Director, Business Development

 

DMF/lec

 

* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.

 Confidential

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]